Abstract:Butyrate, a metabolite produced by gut bacteria, has demonstrated beneficial effects in the colon and has been used to treat inflammatory bowel diseases. However, the mechanism by which butyrate operates remains incompletely understood. Given that oral butyrate can exert either a direct impact on the gut mucosa or an indirect influence through its interaction with the gut microbiome, this study aimed to investigate three key aspects: (1) whether oral intake of butyrate modulates the expression of genes encoding short-chain fatty acid (SCFA) transporters ( Slc16a1 , Slc16a3 , Slc16a4 , Slc5a8 , Abcg2 ) and receptors ( Hcar2 , Ffar2 , Ffar3 , Olfr78 , Olfr558 ) in the colon, (2) the potential involvement of gut microbiota in this modulation, and (3) the impact of oral butyrate on the expression of colonic SCFA transporters and receptors during colonic inflammation. Specific pathogen-free (SPF) and germ-free (GF) mice with or without DSS-induced inflammation were provided with either water or a 0.5% sodium butyrate solution. The findings revealed that butyrate decreased the expression of Slc16a1 , Slc5a8 , and Hcar2 in SPF but not in GF mice, while it increased the expression of Slc16a3 in GF and the efflux pump Abcg2 in both GF and SPF animals. Moreover, the presence of microbiota was associated with the upregulation of Hcar2 , Ffar2, and Ffar3 expression and the downregulation of Slc16a3 . Interestingly, the challenge with DSS did not alter the expression of SCFA transporters, regardless of the presence or absence of microbiota, and the effect of butyrate on the transporter expression in SPF mice remained unaffected by DSS. The expression of SCFA receptors was only partially affected by DSS. Our results indicate that (1) consuming a relatively low concentration of butyrate can influence the expression of colonic SCFA transporters and receptors, with their expression being modulated by the gut microbiota, (2) the effect of butyrate does not appear to result from direct substrate-induced regulation but rather reflects an indirect effect associated with the gut microbiome, and (3) acute colon inflammation does not lead to significant changes in the transcriptional regulation of most SCFA transporters and receptors, with the effect of butyrate in the inflamed colon remaining intact.

Butyrate as a Potential Driver of a Dysbiotic Shift of the Tongue Microbiota

Microbial Characteristics Across Different Tongue Coating Types in a Healthy Population

Oral Microbiota: The Influences and Interactions of Saliva, IgA, and Dietary Factors in Health and Disease

A Double-Edged Sword: Role Of Butyrate In The Oral Cavity And The Gut

Butyrate Prevents the Pathogenic Anemia‐Inflammation Circuit by Facilitating Macrophage Iron Export

ROLE OF GUT MICROBIOME HOMEOSTASIS, INTEGRITY OF THE INTESTINAL EPITHELIAL CELLS, AND THE (ENDOGENOUS) BUTYRATE IN ENDURING A HEALTHY LONG LIFE

Oral care tablet containing kiwifruit powder affects tongue coating microbiome

Why does increased microbial fermentation in the human colon shift toward butyrate?

The effect of oral butyrate on colonic short-chain fatty acid transporters and receptors depends on microbial status

Crosstalk between butyrate oxidation in colonocyte and butyrate-producing bacteria

Oral-to-rectum microbial transmission in orthopedic patients without a history of intestinal disorders

Insight into the Relationship between Oral Microbiota and the Inflammatory Bowel Disease

BUTYRATE-PRODUCING BACTERIA INCREASE GUT MICROBIOTA DIVERSITY TO DELAY INTESTINAL INFLAMMAGING

The Bacterial Connection between the Oral Cavity and the Gut Diseases

The interplay between gut microbiota, short-chain fatty acids, and implications for host health and disease

Metabolic Engineering of Commensal Bacteria for Gut Butyrate Delivery and Dissection of Host-Microbe Interaction.

Dysbiotic human oral microbiota alters systemic metabolism via modulation of gut microbiota in germ-free mice

Dietary Vitamin B1 Intake Influences Gut Microbial Community and the Consequent Production of Short-Chain Fatty Acids

Antioxidant Vitamins and Prebiotic FOS and XOS Differentially Shift Microbiota Composition and Function and Improve Intestinal Epithelial Barrier In Vitro

A Synbiotic Formulation Comprising Bacillus subtilis DSM 32315 and L-Alanyl-L-Glutamine Improves Intestinal Butyrate Levels and Lipid Metabolism in Healthy Humans

Effect of the probiotic Weissella cibaria CMS1 on the immune response and the oral microbiome: a randomized, double-blind, placebo-controlled, parallel study